Skip to main content
. 2021 Jul 5;9(7):e002261. doi: 10.1136/jitc-2020-002261

Figure 6.

Figure 6

Overall survival in those who received CS ≥2 months after initiation of CPI (blue line) versus those who received CS <2 months after initiation of CPI (red line) in those who were treated with CS for non-irAEs indications. CPI, checkpoint inhibitor; CS, corticosteroid; irAE, immune-related adverse effect; OS, overall survival.